Welcome to STN International! Enter x:x

LOGINID:

Welcome to STN International! Enter x:x

LOGINID:ssspta1125rxt

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated

```
 NEWS 39  May 16  CHEMREACT will be removed from STN
 NEWS 40  May 19  Simultaneous left and right truncation added to WSCA
 NEWS 41  May 19  RAPRA enhanced with new search field, simultaneous left and
                  right truncation
 NEWS 42  Jun 06  Simultaneous left and right truncation added to CBNB
 NEWS 43  Jun 06  PASCAL enhanced with additional data
 NEWS 44  Jun 20  2003 edition of the FSTA Thesaurus is now available
 NEWS 45  Jun 25  HSDB has been reloaded

 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:35:36 ON 25 JUN 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:35:56 ON 25 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 JUN 2003  HIGHEST RN 536971-45-6
DICTIONARY FILE UPDATES:  24 JUN 2003  HIGHEST RN 536971-45-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e mycophenolic
E1            1     MYCOPHENOLAMIDE/BI
E2            8     MYCOPHENOLATE/BI
```

```
E3          10 --> MYCOPHENOLIC/BI
E4           9     MYCOPHILUS/BI
E5           1     MYCOPHYT/BI
E6          14     MYCOPLANA/BI
E7          44     MYCOPLANECIN/BI
E8           1     MYCOPLANECINUS/BI
E9           3     MYCOPLAS/BI
E10       7098     MYCOPLASMA/BI
E11          1     MYCOPLASMAS/BI
E12          1     MYCOPLASMASIN/BI

=> s e3
L1          10 MYCOPHENOLIC/BI

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.02       5.23

FILE 'CAPLUS' ENTERED AT 12:37:00 ON 25 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Jun 2003  VOL 138 ISS 26
FILE LAST UPDATED: 24 Jun 2003  (20030624/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l1
L2          799 L1

=> s hiv or retroviral
         49886 HIV
         13518 RETROVIRAL
L3       61070 HIV OR RETROVIRAL

=> s l2 andl3
MISSING OPERATOR L2 ANDL3
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l2 and l3
L4           21 L2 AND L3

=> d l4 10-21

L4   ANSWER 10 OF 21  CAPLUS  COPYRIGHT 2003 ACS
AN   2000:502615  CAPLUS
```

DN 133:171813
TI Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo
AU Chapuis, Aude G.; Rizzardi, G. Paolo; D'Agostino, Claudia; Attinger, Antoine; Knabenhans, Christian; Fleury, Sylvain; Acha-Orbea, Hans; Pantaleo, Giuseppe
CS Laboratory of AIDS Immunnopathogenesis, Department of Medicine, Division of lnfectious Diseases, Centre Hospitalier Universitaire Vauidois, University of Lausanne, Lausamnne, 1011, Switz.
SO Nature Medicine (New York) (2000), 6(7), 762-768
CODEN: NAMEFI; ISSN: 1078-8956
PB Nature America Inc.
DT Journal
LA English
RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 2000:431967 CAPLUS
DN 133:261112
TI Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant **HIV**-1
AU Heredia, Alonso; Margolis, David; Oldach, David; Hazen, Richard; Le, Nhut; Redfield, Robert
CS Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, Baltimore, MD, USA
SO JAIDS, Journal of Acquired Immune Deficiency Syndromes (1999), 22(4), 406-407
CODEN: JJASFJ
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 2000:402042 CAPLUS
DN 133:39138
TI Cell cycle regulating centrosomin CNN-4 and its gene from Drosophila melanogaster
IN Kaufman, Thomas C.; Megraw, Timothy L.; Cecil, Jeffrey K.
PA Advanced Research and Technology Institute, USA
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000034524	A1	20000615	WO 1999-US29251	19991208

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-111823P P 19981211
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 2000:339739 CAPLUS
DN 133:202773
TI Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-**HIV** activity
AU Margolis, David; Heredia, Alonso; Gaywee, Jariyanart; Oldach, David; Drusano, George; Redfield, Robert
CS University of Maryland Institute of Human Virology, Baltimore, MD, 21201, USA
SO JAIDS, Journal of Acquired Immune Deficiency Syndromes (1999), 21(5), 362-370
CODEN: JJASFJ
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1997:418518 CAPLUS
DN 127:50464
TI Computer-assisted design and synthesis of analogs of mycophenolic acid as antitumor and anti-**HIV** agents
AU Makara, Gergely M.
CS State Univ. of New York, Buffalo, NY, USA
SO (1997) 173 pp. Avail.: UMI, Order No. DA9719149
From: Diss. Abstr. Int., B 1997, 58(1), 206
DT Dissertation
LA English

L4 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1995:755015 CAPLUS
DN 123:160186
TI Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus
AU Ichimura, Hiroshi; Levy, Jay A.
CS Cancer Res. Inst., Univ. California, San Francisco, CA, 94143, USA
SO Virology (1995), 211(2), 554-60
CODEN: VIRLAX; ISSN: 0042-6822
PB Academic
DT Journal
LA English

L4 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1994:182534 CAPLUS
DN 120:182534
TI Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication
AU Mroz, Paula J.; Moolten, Frederick L.
CS Edith Nourse Rogers Mem. Veterans Hosp., Bedford, MA, 01730, USA
SO Human Gene Therapy (1993), 4(5), 589-95
CODEN: HGTHE3; ISSN: 1043-0342
DT Journal
LA English

L4 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1993:440505 CAPLUS
DN 119:40505
TI Polyionic compounds selectively alter availability of CD4 receptors for **HIV** coat protein rgp120

AU Aszalos, A.; Pine, P. S.; Weaver, J.
CS Food and Drug Adm., Washington, DC, USA
SO Mol. Aspects Chemother., Proc. Int. Symp., 3rd (1992), Meeting Date 1991, 209-17. Editor(s): Shugar, David; Rode, Wojciech; Borowski, Edward. Publisher: Springer, Berlin, Germany.
CODEN: 59CSAM
DT Conference
LA English

L4 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1991:505536 CAPLUS
DN 115:105536
TI Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine
AU Hartman, Neil R.; Ahluwalia, Gurpreet S.; Cooney, David A.; Mitsuya, Hiroaki; Kageyama, Seiji; Fridland, Arnold; Broder, Samuel; Johns, David G.
CS Lab. Med. Chem., Natl. Cancer Inst., Bethesda, MD, 20892, USA
SO Molecular Pharmacology (1991), 40(1), 118-24
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English

L4 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1991:74748 CAPLUS
DN 114:74748
TI Polyionic compounds selectively alter availability of CD4 receptors for **HIV** coat protein rgp120
AU Weaver, James L.; Gergely, Peter; Pine, P. Scott; Patzer, Eric; Aszalos, Adorjan
CS Food and Drug Adm., Washington, DC, 20204, USA
SO AIDS Research and Human Retroviruses (1990), 6(9), 1125-30
CODEN: ARHRE7; ISSN: 0889-2229
DT Journal
LA English

L4 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1990:604479 CAPLUS
DN 113:204479
TI Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2',3'-dideoxyguanosine
AU Ahluwalia, Gurpreet; Cooney, David A.; Bondoc, Laureano L., Jr.; Currens, Michael J.; Ford, Harry; Johns, David G.; Mitsuya, Hiroaki; Fridland, Arnold
CS Div. Cancer Treat., Natl. Cancer Inst., Bethesda, MD, 20892, USA
SO Biochemical and Biophysical Research Communications (1990), 171(3), 1297-303
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English

L4 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1989:449969 CAPLUS
DN 111:49969
TI Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compounds
AU Seki, Junichi; Shimada, Nobuyoshi; Takahashi, Katsutoshi; Takita, Tomohisa; Takeuchi, Tomio; Hoshino, Hiroo
CS Sch. Med., Gunma Univ., Maebashi, 371, Japan
SO Antimicrobial Agents and Chemotherapy (1989), 33(5), 773-5
CODEN: AMACCQ; ISSN: 0066-4804

DT Journal
LA English

=> d 14 13 all

L4 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 2000:339739 CAPLUS
DN 133:202773
TI Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-**HIV** activity
AU Margolis, David; Heredia, Alonso; Gaywee, Jariyanart; Oldach, David; Drusano, George; Redfield, Robert
CS University of Maryland Institute of Human Virology, Baltimore, MD, 21201, USA
SO JAIDS, Journal of Acquired Immune Deficiency Syndromes (1999), 21(5), 362-370
CODEN: JJASFJ
PB Lippincott Williams & Wilkins
DT Journal
LA English
CC 1-7 (Pharmacology)
AB The use of inhibitors of purine nucleoside metab. has been advocated for the treatment of **HIV**-1 infection. Abacavir is the first clin. available guanosine analog **HIV**-1 reverse transcriptase inhibitor, and the most potent nucleoside analog yet developed. Mycophenolic acid (MA), a specific inhibitor of lymphocyte proliferation that is currently in use in organ transplantation, acts on inosine monophosphate dehydrogenase to block the conversion of inosine monophosphate to guanosine monophosphate. The authors found Abacavir and MA inhibited **HIV**-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) and in monocyte-derived macrophages (MDMs). Inhibition was potent and synergistic to an extent not previously obsd. with other antiretroviral combinations. MA was effective at concns. (0.25 .mu.M) far below those used for immunosuppression in organ transplantation. An **HIV** strain encoding the M184V mutation was susceptible to the combination of MA and Abacavir. However, the combination of MA and zidovudine (ZDV) or stavudine (d4T) was antagonistic. Although the translation of these observations must be carefully evaluated in clin. trials, the judicious combination of antiretrovirals and inhibitors of nucleoside metab. may emerge as an important strategy in the treatment of **HIV** infection.
ST **HIV** inhibitor Abacavir mycophenolate
IT Human immunodeficiency virus 1
(profound and synergistic anti-**HIV** activity of Abacavir and mycophenolic acid)
IT Nucleosides, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(profound and synergistic anti-**HIV** activity of Abacavir and mycophenolic acid in relation to nucleoside metab.)
IT 9028-93-7, Inosine monophosphate dehydrogenase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(profound and synergistic anti-**HIV** activity of Abacavir and mycophenolic acid)
IT **24280-93-1**, Mycophenolic acid 136470-78-5, Abacavir
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(profound and synergistic anti-**HIV** activity of Abacavir and mycophenolic acid)
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Allison, A; Ann NY Acad Sci 1993, V696, P63 CAPLUS
(2) Allison, A; Transplant Proc 1991, V23(Suppl 2), P10
(3) Anon; ACTG virology manual 1994
(4) Anon; Ziagen package insert 1999
(5) Baba, M; Antimicrob Agents Chemother 1987, V31, P1613 CAPLUS
(6) Barti, P; Presented at the 6th Conference on Retroviruses and Opportunistic Infections 1999
(7) Bianchi, V; Proc Natl Acad Sci USA 1994, V91, P8403 CAPLUS
(8) Biron, F; Antiviral Res 1996, V29, P111 CAPLUS
(9) Biron, F; J Acquir Immune Defic Syndr Hum Retrovirol 1995, V10, P36 CAPLUS
(10) Bullingham, R; Transplant Proc 1996, V28, P925 CAPLUS
(11) Carr, S; J Biol Chem 1993, V268, P27286 CAPLUS
(12) Chenge-Mayer, C; Ann Neurol 1988, V23, PS58
(13) Dayton, J; Mol Pharmacol 1994, V41, P671
(14) De Boer, R; AIDS 1998, V12, P1567 MEDLINE
(15) Drusano, G; Antimicrob Agents Chemother 1998, V42, P2153 CAPLUS
(16) D'Argenio, D; ADAPT II: a program package for simulation identification and optimal experimental design 1990
(17) Gao, W; Mol Pharmacol 1994, V46, P767 CAPLUS
(18) Gao, W; Proc Natl Acad Sci USA 1993, V90, P8925 CAPLUS
(19) Gao, W; Proc Natl Acad Sci USA 1995, V92, P8333 CAPLUS
(20) Giacca, M; J Infect Dis 1996, V174, P204 CAPLUS
(21) Greco, W; Pharmacol Rev 1995, V47, P331 MEDLINE
(22) Harada, S; Science 1985, V229, P563 MEDLINE
(23) Hartman, N; Mol Pharmacol 1991, V40, P118 CAPLUS
(24) Ichimura, H; Virology 1995, V211, P554 CAPLUS
(25) Johns, D; Biochem Pharmacol 1998, V55, P1551 CAPLUS
(26) Lanier, R; Presented at the 6th Conference on Retroviruses and Opportunistic Infections 1999
(27) Lori, F; AIDS Res Hum Retroviruses 1997, V13, P1403 CAPLUS
(28) Lori, F; Science 1994, V266, P801 CAPLUS
(29) Luzzati, R; J Antimicrob Chemother 1998, V42, P565 CAPLUS
(30) Malley, S; Proc Natl Acad Sci USA 1994, V91, P11017 CAPLUS
(31) Meyerhans, A; J Virol 1994, V68, P535 CAPLUS
(32) Montaner, J; J Infect Dis 1997, V175, P801 CAPLUS
(33) Neyts, J; Antimicrob Agents Chemother 1998, V42, P216 CAPLUS
(34) Neyts, J; Antimicrob Agents Chemother 1998, V42, P3285 CAPLUS
(35) Perno, C; Current Protocols in Immunology 1993, Suppl 5, P12.4.4
(36) Popovic, M; Science 1984, V224, P497 MEDLINE
(37) Roche Laboratories; Cellcept package insert 1998
(38) Rutschmann, O; AIDS 1998, V12, PF71 CAPLUS
(39) Schinazy, R; Antimicrob Agents Chemother 1993, V37, P875
(40) Staszeweski, S; Presented at the 6th Conference on Retroviruses and Opportunistic Infections 1999
(41) Tisdale, M; Antimicrob Agents Chemother 1997, V41, P1094 CAPLUS
(42) Vila, J; Lancet 1996, V348, P203 MEDLINE
(43) Vogt, M; Science 1987, V235, P1376 CAPLUS

=> d 14 15 all

L4 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1995:755015 CAPLUS
DN 123:160186
TI Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus
AU Ichimura, Hiroshi; Levy, Jay A.
CS Cancer Res. Inst., Univ. California, San Francisco, CA, 94143, USA
SO Virology (1995), 211(2), 554-60
CODEN: VIRLAX; ISSN: 0042-6822
PB Academic
DT Journal

LA English
CC 1-5 (Pharmacology)
AB Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase, shows strong anti-**HIV** activity in vitro in both human peripheral blood CD4+ lymphocytes and macrophages, as well as established human cell lines. MPA shows its greatest antiviral effects during the early stages of **HIV** infection. By limiting the rate of de novo synthesis of guanosine nucleotides, this drug apparently blocks the activity of reverse transcriptase, which is required for the formation of the **HIV** DNA provirus. MPA provides a novel strategy for inhibiting the replication of **HIV** and should be considered in clin. trials of antiviral therapies.
ST polymerase substrate depletion **HIV** replication; mycophenolic acid **HIV** inhibition reverse transcriptase
IT Blood
Lymphocyte
Macrophage
Virucides and Virustats
(**HIV**-1 reverse transcriptase inhibition and polymerase substrate depletion by mycophenolic acid)
IT Nucleotides, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibition of guanosine nucleotides by mycophenolic acid and anti-**HIV**-1 activity)
IT Virus, animal
(human immunodeficiency 1, **HIV**-1 reverse transcriptase inhibition and polymerase substrate depletion by mycophenolic acid)
IT **24280-93-1**, Mycophenolic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**HIV**-1 reverse transcriptase inhibition and polymerase substrate depletion by mycophenolic acid)
IT 9068-38-6, Reverse transcriptase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**HIV**-1 reverse transcriptase inhibition and polymerase substrate depletion by mycophenolic acid)
IT 118-00-3D, Guanosine, nucleotides
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibition of guanosine nucleotides by mycophenolic acid and anti-**HIV**-1 activity)

=> d l4 20 all

L4 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2003 ACS
AN 1990:604479 CAPLUS
DN 113:204479
TI Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2',3'-dideoxyguanosine
AU Ahluwalia, Gurpreet; Cooney, David A.; Bondoc, Laureano L., Jr.; Currens, Michael J.; Ford, Harry; Johns, David G.; Mitsuya, Hiroaki; Fridland, Arnold
CS Div. Cancer Treat., Natl. Cancer Inst., Bethesda, MD, 20892, USA
SO Biochemical and Biophysical Research Communications (1990), 171(3), 1297-303
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English

CC 1-5 (Pharmacology)

AB The inosinate dehydrogenase (IMPD) inhibitors ribavirin, tiazofurin and mycophenolic acid were found to stimulate by as much as 20-fold the anabolism of the anti-**HIV** agent 2',3'-dideoxyguanosine to its 5'-diphosphate (ddGDP) in a human T-cell culture system (Molt-4 cells). Stimulation of the further conversion to ddGTP (the active form of the drug) was lesser in magnitude but still highly significant (up to 4-fold at appropriate concns. of ribavirin or tiazofurin). In parallel with these increases, the inhibitors also produced increases of up to 35-fold in IMP levels. These results support the proposal that the initial phosphorylation of ddGuo is catalyzed by a phosphotransferase (5'-nucleotidase) which utilizes IMP as its phosphate donor (Johnson and Fridland, [1989] Molec. Pharmacol. 36, 291-295). Concomitant with this increase in 5'-phosphorylation of ddGuo, an increase in its anti-**HIV** activity of up to 6.5-fold was obsd. when this agent was combined with ribavirin (5.mu.M) in the CEM cell assay system.

ST antiviral nucleoside phosphorylation IMP dehydrogenase inhibitor; inhibition dideoxyguanosine IMP dehydrogenase inhibitor

IT Lymphocyte
(T-, dideoxyguanosine phosphorylation by human, IMP dehydrogenase inhibitors stimulation of, **HIV** inhibition in relation to)

IT Virus, animal
(human immunodeficiency 1, III.beta., inhibition of, by dideoxyguanosine and IMP dehydrogenase inhibitors, in human T-lymphocytes)

IT Microbicidal and microbiostatic action
(virucidal, of dideoxyguanosine and IMP dehydrogenase inhibitors, in human T-lymphocytes)

IT 68726-28-3 84328-12-1 85956-71-4
RL: BIOL (Biological study)
(as dideoxyguanosine metabolite, in human T-lymphocytes, IMP dehydrogenase inhibitors effect on)

IT **24280-93-1**, NSC 129185 36791-04-5, NSC 163039 60084-10-8, NSC 286193
RL: BIOL (Biological study)
(dideoxyguanosine phosphorylation by T-lymphocytes of humans stimulation by, **HIV** inhibition in relation to)

IT 9028-93-7, IMP dehydrogenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, dideoxyguanosine phosphorylation by T-lymphocytes of humans stimulation by, **HIV** inhibition in relation to)

IT 131-99-7, IMP
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metab. of, by T-lymphocytes of humans, dideoxyguanosine metab. response to IMP dehydrogenase inhibitors in relation to)

IT 85326-06-3
RL: BIOL (Biological study)
(phosphorylation of, by T-lymphocytes of humans, IMP dehydrogenase inhibitors stimulation of, **HIV** inhibition in relation to)

=> d 14 21 all

L4 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2003 ACS

AN 1989:449969 CAPLUS

DN 111:49969

TI Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compounds

AU Seki, Junichi; Shimada, Nobuyoshi; Takahashi, Katsutoshi; Takita, Tomohisa; Takeuchi, Tomio; Hoshino, Hiroo

CS Sch. Med., Gunma Univ., Maebashi, 371, Japan

SO Antimicrobial Agents and Chemotherapy (1989), 33(5), 773-5
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English
CC 1-5 (Pharmacology)
GI



I

AB Oxetanocin A (I) is a novel nucleoside contg. a 4-membered sugar, oxetanosyl-N-glycoside, and adenine. The effects of oxetanocin and related compds. on the infectivity of human immunodeficiency virus (**HIV**) were examd. They inhibited **HIV** infectivity in vitro. Allopurinol and mycophenolic acid produced additive anti-**HIV** effects when added with these compds.
ST oxetanocin analog human immunodeficiency virus
IT Virus, animal
(human immunodeficiency 1, inhibition of, by oxetanocin analogs, allopurinol and mycophenolic acid enhancement of)
IT 315-30-0 **24280-93-1**, Mycophenolic acid
RL: BIOL (Biological study)
(human immunodeficiency virus inhibition by oxetanocin analogs enhancement by)
IT 103913-16-2 113269-44-6 113269-45-7 113269-46-8 113296-23-4
RL: BIOL (Biological study)
(human immunodeficiency virus inhibition by, allopurinol and mycophenolic acid enhancement of)

=> d his

(FILE 'HOME' ENTERED AT 12:35:36 ON 25 JUN 2003)

FILE 'REGISTRY' ENTERED AT 12:35:56 ON 25 JUN 2003
E MYCOPHENOLIC
L1 10 S E3

FILE 'CAPLUS' ENTERED AT 12:37:00 ON 25 JUN 2003
L2 799 S L1
L3 61070 S HIV OR RETROVIRAL
L4 21 S L2 AND L3

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.59	35.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.60	-2.60

STN INTERNATIONAL LOGOFF AT 12:43:06 ON 25 JUN 2003

Welcome to STN International! Enter x:x

LOGINID:ssspta1125rxt

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 42	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 43	Jun 06	PASCAL enhanced with additional data

```
 NEWS 44  Jun 20  2003 edition of the FSTA Thesaurus is now available
 NEWS 45  Jun 25  HSDB has been reloaded

 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:19:12 ON 25 JUN 2003

=> file reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:19:20 ON 25 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 JUN 2003  HIGHEST RN 536971-45-6
DICTIONARY FILE UPDATES:  24 JUN 2003  HIGHEST RN 536971-45-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> ribavirin
RIBAVIRIN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s ribavirin
L1          17 RIBAVIRIN
```

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         4.62       4.83

FILE 'CAPLUS' ENTERED AT 15:19:41 ON 25 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 25 Jun 2003  VOL 138 ISS 26
FILE LAST UPDATED: 24 Jun 2003  (20030624/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l1
L2        1626 L1

=> s hiv or retroviral or retrovirus
         49886 HIV
         13518 RETROVIRAL
         11616 RETROVIRUS
L3       66831 HIV OR RETROVIRAL OR RETROVIRUS

=> s l2 and l3
L4         118 L2 AND L3

=> d l4 90-118

L4   ANSWER 90 OF 118  CAPLUS  COPYRIGHT 2003 ACS
AN   1992:98734  CAPLUS
DN   116:98734
TI   Antiviral portrait series.  Number 2.  The activity of ribavirin against
     the human immunodeficiency virus:  a review of laboratory and clinical
     experience
AU   Snell, N. J. C.
CS   Eur. Med. Aff. Dep., ICN Pharm., High Wycombe, HP13 7DL, UK
SO   Antiviral Chemistry & Chemotherapy (1991), 2(5), 257-63
     CODEN: ACCHEH; ISSN: 0956-3202
DT   Journal; General Review
LA   English

L4   ANSWER 91 OF 118  CAPLUS  COPYRIGHT 2003 ACS
AN   1992:55426  CAPLUS
DN   116:55426
TI   Differential inhibitory effects of sulfated polysaccharides and polymers
     on the replication of various myxoviruses and retroviruses, depending on
     the composition of the target amino acid sequences of the viral envelope
     glycoproteins
```

AU Hosoya, Mitsuaki; Balzarini, Jan; Shigeta, Shiro; De Clercq, Erik
CS Rega Inst. Med. Res., Kathol. Univ. Leuven, Louvain, B-3000, Belg.
SO Antimicrobial Agents and Chemotherapy (1991), 35(12), 2515-20
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English

L4 ANSWER 92 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:597811 CAPLUS
DN 115:197811
TI Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus
AU Balzarini, Jan; Lee, Chong Kyo; Herdewijn, Piet; De Clercq, Erik
CS Rega Inst. Med. Res., Kathol. Univ., Louvain, B-3000, Belg.
SO Journal of Biological Chemistry (1991), 266(32), 21509-14
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English

L4 ANSWER 93 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:526477 CAPLUS
DN 115:126477
TI 1-.beta.-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethnyl-1-.beta.-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2',3'-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes
AU Balzarini, Jan; Lee, Chong Kyo; Schols, Dominique; De Clercq, Erik
CS Rega Inst. Med. Res., Kathol. Univ. Leuven, Louvain, B-3000, Belg.
SO Biochemical and Biophysical Research Communications (1991), 178(2), 563-9
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English

L4 ANSWER 94 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:505536 CAPLUS
DN 115:105536
TI Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine
AU Hartman, Neil R.; Ahluwalia, Gurpreet S.; Cooney, David A.; Mitsuya, Hiroaki; Kageyama, Seiji; Fridland, Arnold; Broder, Samuel; Johns, David G.
CS Lab. Med. Chem., Natl. Cancer Inst., Bethesda, MD, 20892, USA
SO Molecular Pharmacology (1991), 40(1), 118-24
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English

L4 ANSWER 95 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:484878 CAPLUS
DN 115:84878
TI Inhibition of human immunodeficiency virus type 1 replication by guanosine analogs and lack of synergistic antiviral effect of acyclovir with 3'-azido-3'-deoxythymidine
AU Smith, M. S.; Pagano, J. S.
CS Lineberger Cancer Res. Cent., Univ. North Carolina, Chapel Hill, NC, 27599, USA
SO Antiviral Chemistry & Chemotherapy (1991), 2(1), 29-34
CODEN: ACCHEH; ISSN: 0956-3202
DT Journal
LA English

L4 ANSWER 96 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:400777 CAPLUS
DN 115:777
TI Treatment of human **retroviral** infections with 2',3'-dideoxyinosine
IN Yarchoan, Robert; Mitsuya, Hiroaki; Broder, Samuel
PA National Institutes of Health, USA
SO U. S. Pat. Appl., 29 pp. Avail. NTIS Order No. PAT-APPL-7-460 490.
CODEN: XAXXAV
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 460490	A0	19910201	US 1990-460490	19900103
	US 5026687	A	19910625		
	CA 2072573	AA	19910704	CA 1991-2072573	19910103
	CA 2072573	C	19960528		
	WO 9109605	A1	19910711	WO 1991-US5	19910103
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AU 9171757	A1	19910724	AU 1991-71757	19910103
	AU 643976	B2	19931202		
	EP 509019	A1	19921021	EP 1991-902028	19910103
	EP 509019	B1	19980715		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05506007	T2	19930902	JP 1991-502953	19910103
	JP 2829545	B2	19981125		
	AT 168268	E	19980815	AT 1991-902028	19910103
	ES 2125233	T3	19990301	ES 1991-902028	19910103
	US 5376642	A	19941227	US 1993-26188	19930301
PRAI	US 1990-460490		19900103		
	WO 1991-US5		19910103		
	US 1991-669846		19910315		

L4 ANSWER 97 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:400257 CAPLUS
DN 115:257
TI Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside
AU Balzarini, Jan; Naesens, Lieve; Robins, Morris J.; De Clercq, Erik
CS Rega Inst. Med. Res., Cathol. Univ. Leuven, Louvain, B-3000, Belg.
SO Journal of Acquired Immune Deficiency Syndromes (1990), 3(12), 1140-7
CODEN: JAISET; ISSN: 0894-9255
DT Journal
LA English

L4 ANSWER 98 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:177932 CAPLUS
DN 114:177932
TI Mechanism of action of Ribavirin on Bunyavirus infected cells
AU Patterson, J. L.
CS Child. Hosp. Corp., Boston, MA, USA
SO Report (1989), Order No. AD-A218936, 13 pp. Avail.: NTIS
From: Gov. Rep. Announce. Index (U. S.) 1990, 90(13), Abstr. No. 034,443
DT Report
LA English

L4 ANSWER 99 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:55350 CAPLUS
DN 114:55350

TI Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase
AU Fernandez-Larsson, Roberto; Patterson, Jean L.
CS Div. Infect. Dis., Child. Hosp., Boston, MA, 02115, USA
SO Molecular Pharmacology (1990), 38(6), 766-70
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English

L4 ANSWER 100 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1990:604479 CAPLUS
DN 113:204479
TI Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2',3'-dideoxyguanosine
AU Ahluwalia, Gurpreet; Cooney, David A.; Bondoc, Laureano L., Jr.; Currens, Michael J.; Ford, Harry; Johns, David G.; Mitsuya, Hiroaki; Fridland, Arnold
CS Div. Cancer Treat., Natl. Cancer Inst., Bethesda, MD, 20892, USA
SO Biochemical and Biophysical Research Communications (1990), 171(3), 1297-303
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English

L4 ANSWER 101 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1990:604470 CAPLUS
DN 113:204470
TI Virucidal activity of hypericin against enveloped and nonenveloped DNA and RNA viruses
AU Tang, Joseph; Colacino, Joseph M.; Larsen, Stephen H.; Spitzer, Wayne
CS Lilly Res. Lab., Indianapolis, IN, 46285, USA
SO Antiviral Research (1990), 13(6), 313-25
CODEN: ARSRDR; ISSN: 0166-3542
DT Journal
LA English

L4 ANSWER 102 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1990:503397 CAPLUS
DN 113:103397
TI Porphyrin and phthalocyanine antiviral compositions
IN Schinazi, Raymond F.; Dixon, Dabney White; Marzilli, Luigi G.
PA Georgia State University Foundation, Inc., USA
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8911277	A2	19891130	WO 1989-US2256	19890523
	WO 8911277	A3	19891228		
	W: AU, DK, FI, JP, KR, NO				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 5192788	A	19930309	US 1988-197764	19880523
	US 5109016	A	19920428	US 1989-355499	19890522
	AU 8938306	A1	19891212	AU 1989-38306	19890523
	US 5281616	A	19940125	US 1992-873415	19920424
PRAI	US 1988-197764		19880523		
	US 1989-355499		19890522		
	US 1989-355499		19890522		
	US 1989-355499		19890522		
	US 1989-355499		19890522		

US 1989-355499 19890522
WO 1989-US2256 19890523

L4 ANSWER 103 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1990:217469 CAPLUS
DN 112:217469
TI Preparation of purine nucleosides as antiviral agents and pharmaceutical compositions containing them
IN Vince, Robert; Shannon, William M.
PA University of Minnesota, USA; Southern Research Institute
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 346132	A1	19891213	EP 1989-305829	19890609
	EP 346132	B1	19920311		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DK 8902841	A	19891211	DK 1989-2841	19890609
	AU 8936272	A1	19891214	AU 1989-36272	19890609
	AU 627188	B2	19920820		
	JP 02091022	A2	19900330	JP 1989-145534	19890609
	ZA 8904392	A	19900829	ZA 1989-4392	19890609
	AT 73335	E	19920315	AT 1989-305829	19890609
	US 5122517	A	19920616	US 1990-611322	19901113
PRAI	US 1988-205163		19880610		
	US 1989-357137		19890530		
	EP 1989-305829		19890609		

OS MARPAT 112:217469

L4 ANSWER 104 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1990:154865 CAPLUS
DN 112:154865
TI Diagnostics and therapy for rheumatoid arthritis
IN Gay, Steffen
PA USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8911285	A1	19891130	WO 1989-US2219	19890522
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 378621	A1	19900725	EP 1989-906918	19890522
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02504429	T2	19901213	JP 1989-506568	19890522
PRAI	US 1988-197554		19880523		
	WO 1989-US2219		19890522		

L4 ANSWER 105 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1990:125216 CAPLUS
DN 112:125216
TI Reverse transcriptase inhibitors for treating adenocarcinomas
IN Hart, Charles Anthony; McCarthy, Kevin; Leinster, Samuel John; Green, Christopher Douglas; Al-Sumidaie, Ayad Mohamed Khala
PA University of Liverpool, UK
SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2.
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8906132	A1	19890713	WO 1989-GB10	19890106
	W: AU, DK, JP, KR, US				
	CA 1331138	A1	19940802	CA 1989-587506	19890104
	ZA 8900093	A	19891025	ZA 1989-93	19890105
	AU 8929498	A1	19890801	AU 1989-29498	19890106
	AU 626284	B2	19920730		
	EP 327200	A1	19890809	EP 1989-300099	19890106
	EP 327200	B1	19921216		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 03503049	T2	19910711	JP 1989-501527	19890106
	JP 2761420	B2	19980604		
	AT 83378	E	19930115	AT 1989-300099	19890106
	CN 1034134	A	19890726	CN 1989-100192	19890107
	DK 9001621	A	19900705	DK 1990-1621	19900705
	DK 173766	B1	20010924		
	US 5223490	A	19930629	US 1990-536669	19900705
PRAI	GB 1988-276	A	19880107		
	EP 1989-300099	A	19890106		
	WO 1989-GB10	A	19890106		

L4 ANSWER 106 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1990:125194 CAPLUS
DN 112:125194
TI Liposomal nucleoside analogs for treating AIDS
IN Hostetler, Karl Y.; Richman, Douglas D.
PA University of California, USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8902733	A1	19890406	WO 1988-US3210	19880919
	W: AU, JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8825261	A1	19890418	AU 1988-25261	19880919
	EP 380558	A1	19900808	EP 1988-908811	19880919
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 03501253	T2	19910322	JP 1988-508005	19880919
PRAI	US 1987-99755		19870922		
	WO 1988-US3210		19880919		

L4 ANSWER 107 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1989:572324 CAPLUS
DN 111:172324
TI Monoclonal antibodies neutralizing **HIV**-1, immunogenic peptides, and their preparation and use in prophylaxis and treatment of **HIV**-1 infection
IN Chang, Tse Wen; Fung, Sek C.; Sun, Cecily Rou Yun; Sun, Bill Nai Chau; Chang, Nancy T.; Liou, Ruey Shyan; Rosen, Edward M.
PA Tanox Biosystems, Inc., USA; Baylor College of Medicine
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8809181	A2	19881201	WO 1988-US1797	19880527
	WO 8809181	A3	19890209		
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 366718	A1	19900509	EP 1988-906589	19880527
	EP 366718	B1	19950510		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 03504556	T2	19911009	JP 1988-506387	19880527
	JP 2520464	B2	19960731		
	AT 122237	E	19950515	AT 1988-906589	19880527
	CA 1339857	A1	19980505	CA 1988-567904	19880527
PRAI	US 1987-57445		19870529		
	US 1987-137861		19871224		
	US 1988-197766		19880523		
	WO 1988-US1797		19880527		

L4 ANSWER 108 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1989:490415 CAPLUS
DN 111:90415
TI Treatment of human viral infection by double-stranded RNA combined with viral inhibitors
IN Carter, William A.
PA Hem Research, Inc., USA
SO Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 286224	A2	19881012	EP 1988-301824	19880302
	EP 286224	A3	19881207		
	EP 286224	B1	19921125		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4950652	A	19900821	US 1987-125097	19871125
	AT 82688	E	19921215	AT 1988-301824	19880302
PRAI	US 1987-28823		19870323		
	US 1987-125097		19871125		
	EP 1988-301824		19880302		

L4 ANSWER 109 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1989:489841 CAPLUS
DN 111:89841
TI Potentiating effect of ribavirin on the antiretrovirus activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside in vitro and in vivo
AU Balzarini, Jan; Herdewijn, Piet; De Clercq, Erik
CS Rega Inst. Med. Res., Kathol. Univ. Leuven, Louvain, B-3000, Belg.
SO Antiviral Research (1989), 11(4), 161-71
CODEN: ARSRDR; ISSN: 0166-3542
DT Journal
LA English

L4 ANSWER 110 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1989:489754 CAPLUS
DN 111:89754
TI Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers
AU Paroni, R.; Del Puppo, M.; Borghi, C.; Sirtori, C. R.; Galli Kienle, M.
CS Ist. Sci. H. S. Raffaele, Milan, Italy

SO International Journal of Clinical Pharmacology, Therapy and Toxicology (1989), 27(6), 302-7
CODEN: IJCPB5; ISSN: 0300-9718
DT Journal
LA English

L4 ANSWER 111 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1989:400255 CAPLUS
DN 111:255
TI In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome
AU Montefiori, David C.; Robinson, W. Edward, Jr.; Mitchell, William M.
CS Sch. Med., Vanderbilt Univ., Nashville, TN, 37232, USA
SO AIDS Research and Human Retroviruses (1989), 5(2), 193-203
CODEN: ARHRE7; ISSN: 0889-2229
DT Journal
LA English

L4 ANSWER 112 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1989:225038 CAPLUS
DN 110:225038
TI Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent
AU Balzarini, Jan; Naesens, Lieve; Herdewijn, Piet; Rosenberg, Ivan; Holy, Antonin; Pauwels, Rudi; Baba, Masanori; Johns, David G.; De Clercq, Erik
CS Rega Inst. Med. Res., Kathol. Univ. Leuven, Louvain, B-3000, Belg.
SO Proceedings of the National Academy of Sciences of the United States of America (1989), 86(1), 332-6
CODEN: PNASA6; ISSN: 0027-8424
DT Journal
LA English

L4 ANSWER 113 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1989:87836 CAPLUS
DN 110:87836
TI Use of continuous human T-lymphocyte H9 culture for screening of chemical drugs inhibiting reproduction of human immunodeficiency virus
AU Nesterchuk, S. L.; Barinskii, I. F.
CS Inst. Virusol., Moscow, USSR
SO Voprosy Virusologii (1988), 33(5), 565-9
CODEN: VVIRAT; ISSN: 0507-4088
DT Journal
LA Russian

L4 ANSWER 114 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1988:204991 CAPLUS
DN 108:204991
TI Synthesis of 2',3'-dideoxyribavirin
AU Sanghvi, Yogesh S.; Hanna, Naeem B.; Larson, Steven B.; Robins, Roland K.; Revankar, Ganapathi R.
CS Nucleic Acid Res. Inst., Costa Mesa, CA, 92626, USA
SO Nucleosides & Nucleotides (1987), 6(4), 761-74
CODEN: NUNUD5; ISSN: 0732-8311
DT Journal
LA English
OS CASREACT 108:204991

L4 ANSWER 115 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1988:31367 CAPLUS
DN 108:31367
TI Study of the effect of Soviet drugs, reaferon, and interferon inducers on

AIDS **retrovirus** reproduction
AU Barinskii, I. F.; Gribencha, S. V.; Nesterchuk, S. L.; Zhdanov, V. M.
CS Inst. Virusol. im. Ivanovskogo, Moscow, USSR
SO Voprosy Virusologii (1987), 32(5), 561-5
CODEN: VVIRAT; ISSN: 0507-4088
DT Journal
LA Russian

L4 ANSWER 116 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1987:628502 CAPLUS
DN 107:228502
TI Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides
AU Frank, Karl B.; McKernan, Patricia A.; Smith, Roberts A.; Smee, Donald F.
CS Nucleic Acid Res. Inst., Costa Mesa, CA, 92626, USA
SO Antimicrobial Agents and Chemotherapy (1987), 31(9), 1369-74
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English

L4 ANSWER 117 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1987:590434 CAPLUS
DN 107:190434
TI Effect of ribamidil and phosphonoformic acid on reproduction in vitro of **retrovirus** HTLV-III
AU Nesterchuk, S. L.; Gribencha, S. V.; Barinskii, I. F.; Zhdanov, V. M.
CS Inst. Virusol. im. Ivanovskogo, Moscow, USSR
SO Voprosy Virusologii (1987), 32(3), 364-6
CODEN: VVIRAT; ISSN: 0507-4088
DT Journal
LA Russian

L4 ANSWER 118 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1987:172809 CAPLUS
DN 106:172809
TI Ribavirin antagonizes the effect of azidothymidine on **HIV** replication
AU Vogt, Markus W.; Hartshorn, Kevan L.; Furman, Phillip A.; Chou, Ting Chao; Fyfe, James A.; Coleman, Leslie A.; Crumpacker, Clyde; Schooley, Robert T.; Hirsch, Martin S.
CS Infect. Dis. Unit, Massachusetts Gen. Hosp., Boston, MA, 02114, USA
SO Science (Washington, DC, United States) (1987), 235(4794), 1376-9
CODEN: SCIEAS; ISSN: 0036-8075
DT Journal
LA English

=> d 14 99 all

L4 ANSWER 99 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:55350 CAPLUS
DN 114:55350
TI Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase
AU Fernandez-Larsson, Roberto; Patterson, Jean L.
CS Div. Infect. Dis., Child. Hosp., Boston, MA, 02115, USA
SO Molecular Pharmacology (1990), 38(6), 766-70
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English
CC 1-5 (Pharmacology)
AB Ribavirin inhibits the human immunodeficiency virus reverse transcriptase

in an in vitro reaction. Ribavirin-5'-diphosphate was close to 40% more inhibitory than ribavirin-5'-triphosphate. Unphosphorylated ribavirin had a reduced, but detectable, effect as an inhibitor, compared with the phosphorylated forms. The compds. seem to have a direct effect on the viral polymerase, and no chain termination was obsd. in the presence of ribavirin-5'-triphosphate. Combination of any of the ribavirin derivs. tested with 3'-azido-3'-deoxythymidine (zidovudine)-5'-triphosphate resulted in an increase of its anti-human immunodeficiency virus reverse transcriptase activity in the in vitro assay.

ST ribavirin **HIV** 1 reverse transcriptase inhibitor

IT Virus, animal
(human immunodeficiency 1, reverse transcriptase of, inhibition by ribavirin and phosphorylated ribavirin and zidovudine)

IT Microbicidal and microbiostatic action
(virucidal, of ribavirin and phosphorylated ribavirin and zidovudine)

IT **36791-04-5**, Ribavirin **63142-70-1**, Ribavirin-5'-diphosphate **63142-71-2**, Ribavirin-5'-triphosphate
RL: BIOL (Biological study)
(**HIV**-1 reverse transcriptase inhibition by)

IT 92586-35-1, Zidovudine-5'-triphosphate
RL: BIOL (Biological study)
(**HIV**-1 reverse transcriptase inhibition by phosphorylated ribavirin and)

IT 9012-90-2, DNA polymerase 9068-38-6, Reverse transcriptase
RL: BIOL (Biological study)
(of **HIV**-1, inhibition by ribavirin and phosphorylated ribavirin and zidovudine)

=> d 14 79 all

L4 ANSWER 79 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1994:153741 CAPLUS
DN 120:153741
TI Use of antiretroviral drugs for treatment of motor neuron diseases
IN Westarp, Martin Egon; Kornhuber, Hans Helmut
PA Germany
SO Ger. Offen., 6 pp.
CODEN: GWXXBX
DT Patent
LA German
IC ICM A61K031-70
ICS A61K031-55; A61K031-505; A61K031-66; A61K031-445; A61K031-47
ICI A61K031-70, A61K031-55, A61K031-505, A61K031-66, A61K031-445, A61K031-47
CC 1-11 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4307883	A1	19930923	DE 1993-4307883	19930312
PRAI	DE 1992-4207863		19920312		

AB Nucleoside analogs and other antiretroviral agents are useful for treatment of diseases of motor neurons, such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and progressive bulbar paralysis. Thus, administration of zidovudine (500 mg/day orally for 2-10 mo) to ALS patients reversed the elevation in serum creatine kinase level characteristic of ALS in 8 of 10 patients.

ST motor nerve disease treatment virucide; amyotrophic lateral sclerosis **retrovirus** drug; zidovudine nerve disease

IT Virucides and Virustats
(for retroviruses, motor neuron disease treatment with)

IT Ribonucleic acids, viral
RL: BIOL (Biological study)

(of **retrovirus**, antisense, motor neuron disease treatment with)
IT Virus, animal
(Maedi-Visna, antisense RNA of, motor neuron disease treatment with)
IT Paralysis
(bulbar, progressive, treatment of, with **retrovirus** inhibitors)
IT Nervous system
(disease, amyotrophic lateral sclerosis, treatment of, with **retrovirus** inhibitors)
IT Nervous system
(disease, spinal muscular atrophy, treatment of, with **retrovirus** inhibitors)
IT Virus, animal
(foamy, antisense RNA of, motor neuron disease treatment with)
IT Nerve, disease
(motor, treatment of, with **retrovirus** inhibitors)
IT Virus, animal
(retro-, inhibitors of, motor neuron disease treatment with)
IT Proteins, specific or class
RL: BIOL (Biological study)
(trichosanthins, motor neuron disease treatment with)
IT 9068-38-6, Reverse transcriptase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, motor neuron disease treatment with)
IT 50-48-6, Amitriptyline 52-67-5 53-43-0, Dehydroepiandrosterone 70-00-8, Trifluorothymidine 360-97-4, 5-Aminoimidazole-4-carboxamide 548-04-9, Hypericin 616-91-1, N-Acetylcysteine 1077-28-7 1077-28-7, 1,2-Dithiolane-3-pentanoic acid 3056-17-5 4317-14-0, Amitriptyline oxide 4408-78-0, Phosphonoacetic acid 4428-95-9, Foscarnet 6493-05-6, Pentoxifylline 6736-58-9, 3-Deazaadenosine 7481-89-2, Dideoxycytidine 9042-14-2, Dextran sulfate 16561-29-8 19130-96-2, Deoxynojirimycin 19750-45-9 30195-30-3 30516-87-1, Azidothymidine **36791-04-5**, Ribavirin 58821-98-0, 12-Deoxyphorbol 13-phenylacetate 59372-48-4, Ammonium antimony tungsten oxide 60857-08-1, 12-Deoxyphorbol 13-acetate 69655-05-6, Dideoxyinosine 72599-27-0 112190-24-6, U-75875 123027-56-5 126347-69-1, R82913 127779-20-8 127875-60-9, A-80915A 129618-40-2, Nevirapine 132774-45-9 132774-46-0 134458-76-7 134678-17-4 134680-32-3 136816-67-6 136816-72-3, U 85961 136816-75-6, U 87201 136816-75-6D, U 87201, esters 136816-76-7, U 88204 136816-84-7, U 88352 136816-85-8, U 88353 136891-12-8 137622-85-6 140459-12-7, Fluorothymidine 143616-58-4 147362-54-7, R 18893 148465-15-0, L697 153374-32-4 153411-01-9 153550-37-9, L 661
RL: BIOL (Biological study)
(motor neuron disease treatment with)

=> d l4 97 all

L4 ANSWER 97 OF 118 CAPLUS COPYRIGHT 2003 ACS
AN 1991:400257 CAPLUS
DN 115:257
TI Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside
AU Balzarini, Jan; Naesens, Lieve; Robins, Morris J.; De Clercq, Erik
CS Rega Inst. Med. Res., Cathol. Univ. Leuven, Louvain, B-3000, Belg.
SO Journal of Acquired Immune Deficiency Syndromes (1990), 3(12), 1140-7
CODEN: JAISET; ISSN: 0894-9255
DT Journal
LA English

CC 1-5 (Pharmacology)
AB The nucleoside analogs, 2',3'-dideoxyinosine (DDI) and 2',3'-dideoxy-2,6-diaminopurine riboside (ddDAPR) are potent and selective inhibitors of human immunodeficiency virus (**HIV**) replication in MT-4 cells. They are also inhibitory to the transformation of C3H/3T3 cells by Moloney murine sarcoma virus (MSV). In vivo, they are only marginally effective in delaying MSV-induced tumor formation, and mortality assocd. therewith in newborn NMRI mice. When combined with ribavirin, DDI and ddDAPR become much more effective in inhibiting MSV and **HIV** replication in vitro and MSV-induced tumor formation in vivo. These observations point to the potential role of ribavirin in the treatment of **retrovirus** infections, particularly in potentiating the anti-**HIV** activity of DDI in AIDS patients.
ST ribavirin deoxynucleoside **retrovirus** inhibition; human immunodeficiency virus inhibition ribavirin deoxynucleoside; **HIV** inhibition ribavirin deoxynucleoside
IT Virucides and Virustats
(dideoxynucleoside-ribavirin combinations as, against **retrovirus**, in human and lab. animal cells)
IT Nucleosides, biological studies
RL: BIOL (Biological study)
(dideoxy, **retrovirus** inhibition by ribavirin and, in human and lab. animal cells)
IT Virus, animal
(human immunodeficiency 1, inhibition of, by dideoxynucleoside-ribavirin combinations, in human cells)
IT Virus, animal
(retro-, inhibition of, by dideoxynucleoside-ribavirin combinations, in human and lab. animal cells)
IT **36791-04-5**, Ribavirin
RL: BIOL (Biological study)
(**retrovirus** inhibition by dideoxynucleosides and, in human and lab. animal cells)
IT 69655-05-6, 2',3'-Dideoxyinosine 107550-73-2
RL: BIOL (Biological study)
(**retrovirus** inhibition by ribavirin and, in human and lab. animal cells)

=> d his

(FILE 'HOME' ENTERED AT 15:19:12 ON 25 JUN 2003)

FILE 'REGISTRY' ENTERED AT 15:19:20 ON 25 JUN 2003
L1 17 S RIBAVIRIN

FILE 'CAPLUS' ENTERED AT 15:19:41 ON 25 JUN 2003
L2 1626 S L1
L3 66831 S HIV OR RETROVIRAL OR RETROVIRUS
L4 118 S L2 AND L3

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	46.73	51.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.95	-1.95

STN INTERNATIONAL LOGOFF AT 15:25:29 ON 25 JUN 2003

AN 1990:604479 CAPLUS
DN 113:204479
TI Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2',3'-dideoxyguanosine
AU Ahluwalia, Gurpreet; Cooney, David A.; Bondoc, Laureano L., Jr.; Currens, Michael J.; Ford, Harry; Johns, David G.; Mitsuya, Hiroaki; Fridland, Arnold
CS Div. Cancer Treat., Natl. Cancer Inst., Bethesda, MD, 20892, USA
SO Biochemical and Biophysical Research Communications (1990), 171(3), 1297-303
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English
CC 1-5 (Pharmacology)
AB The inosinate dehydrogenase (IMPD) inhibitors ribavirin, tiazofurin and mycophenolic acid were found to stimulate by as much as 20-fold the anabolism of the anti-**HIV** agent 2',3'-dideoxyguanosine to its 5'-diphosphate (ddGDP) in a human T-cell culture system (Molt-4 cells). Stimulation of the further conversion to ddGTP (the active form of the drug) was lesser in magnitude but still highly significant (up to 4-fold at appropriate concns. of ribavirin or tiazofurin). In parallel with these increases, the inhibitors also produced increases of up to 35-fold in IMP levels. These results support the proposal that the initial phosphorylation of ddGuo is catalyzed by a phosphotransferase (5'-nucleotidase) which utilizes IMP as its phosphate donor (Johnson and Fridland, [1989] Molec. Pharmacol. 36, 291-295). Concomitant with this increase in 5'-phosphorylation of ddGuo, an increase in its anti-**HIV** activity of up to 6.5-fold was obsd. when this agent was combined with ribavirin (5.mu.M) in the CEM cell assay system.
ST antiviral nucleoside phosphorylation IMP dehydrogenase inhibitor; inhibition dideoxyguanosine IMP dehydrogenase inhibitor
IT Lymphocyte
(T-, dideoxyguanosine phosphorylation by human, IMP dehydrogenase inhibitors stimulation of, **HIV** inhibition in relation to)
IT Virus, animal
(human immunodeficiency 1, III.beta., inhibition of, by dideoxyguanosine and IMP dehydrogenase inhibitors, in human T-lymphocytes)
IT Microbicidal and microbiostatic action
(virucidal, of dideoxyguanosine and IMP dehydrogenase inhibitors, in human T-lymphocytes)
IT 68726-28-3 84328-12-1 85956-71-4
RL: BIOL (Biological study)
(as dideoxyguanosine metabolite, in human T-lymphocytes, IMP dehydrogenase inhibitors effect on)
IT **24280-93-1**, NSC 129185 36791-04-5, NSC 163039 60084-10-8, NSC 286193
RL: BIOL (Biological study)
(dideoxyguanosine phosphorylation by T-lymphocytes of humans stimulation by, **HIV** inhibition in relation to)
IT 9028-93-7, IMP dehydrogenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, dideoxyguanosine phosphorylation by T-lymphocytes of humans stimulation by, **HIV** inhibition in relation to)
IT 131-99-7, IMP
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metab. of, by T-lymphocytes of humans, dideoxyguanosine metab. response to IMP dehydrogenase inhibitors in relation to)
IT 85326-06-3
RL: BIOL (Biological study)
(phosphorylation of, by T-lymphocytes of humans, IMP dehydrogenase

inhibitors stimulation of, **HIV** inhibition in relation to)

=>

AN 1990:604479 CAPLUS
DN 113:204479
TI Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2',3'-dideoxyguanosine
AU Ahluwalia, Gurpreet; Cooney, David A.; Bondoc, Laureano L., Jr.; Currens, Michael J.; Ford, Harry; Johns, David G.; Mitsuya, Hiroaki; Fridland, Arnold
CS Div. Cancer Treat., Natl. Cancer Inst., Bethesda, MD, 20892, USA
SO Biochemical and Biophysical Research Communications (1990), 171(3), 1297-303
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English
CC 1-5 (Pharmacology)
AB The inosinate dehydrogenase (IMPD) inhibitors ribavirin, tiazofurin and mycophenolic acid were found to stimulate by as much as 20-fold the anabolism of the anti-**HIV** agent 2',3'-dideoxyguanosine to its 5'-diphosphate (ddGDP) in a human T-cell culture system (Molt-4 cells). Stimulation of the further conversion to ddGTP (the active form of the drug) was lesser in magnitude but still highly significant (up to 4-fold at appropriate concns. of ribavirin or tiazofurin). In parallel with these increases, the inhibitors also produced increases of up to 35-fold in IMP levels. These results support the proposal that the initial phosphorylation of ddGuo is catalyzed by a phosphotransferase (5'-nucleotidase) which utilizes IMP as its phosphate donor (Johnson and Fridland, [1989] Molec. Pharmacol. 36, 291-295). Concomitant with this increase in 5'-phosphorylation of ddGuo, an increase in its anti-**HIV** activity of up to 6.5-fold was obsd. when this agent was combined with ribavirin (5.mu.M) in the CEM cell assay system.
ST antiviral nucleoside phosphorylation IMP dehydrogenase inhibitor; inhibition dideoxyguanosine IMP dehydrogenase inhibitor
IT Lymphocyte
(T-, dideoxyguanosine phosphorylation by human, IMP dehydrogenase inhibitors stimulation of, **HIV** inhibition in relation to)
IT Virus, animal
(human immunodeficiency 1, III.beta., inhibition of, by dideoxyguanosine and IMP dehydrogenase inhibitors, in human T-lymphocytes)
IT Microbicidal and microbiostatic action
(virucidal, of dideoxyguanosine and IMP dehydrogenase inhibitors, in human T-lymphocytes)
IT 68726-28-3 84328-12-1 85956-71-4
RL: BIOL (Biological study)
(as dideoxyguanosine metabolite, in human T-lymphocytes, IMP dehydrogenase inhibitors effect on)
IT **24280-93-1**, NSC 129185 36791-04-5, NSC 163039 60084-10-8, NSC 286193
RL: BIOL (Biological study)
(dideoxyguanosine phosphorylation by T-lymphocytes of humans stimulation by, **HIV** inhibition in relation to)
IT 9028-93-7, IMP dehydrogenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, dideoxyguanosine phosphorylation by T-lymphocytes of humans stimulation by, **HIV** inhibition in relation to)
IT 131-99-7, IMP
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metab. of, by T-lymphocytes of humans, dideoxyguanosine metab. response to IMP dehydrogenase inhibitors in relation to)
IT 85326-06-3
RL: BIOL (Biological study)
(phosphorylation of, by T-lymphocytes of humans, IMP dehydrogenase

inhibitors stimulation of, **HIV** inhibition in relation to)

=>

AN 1989:449969 CAPLUS
DN 111:49969
TI Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compounds
AU Seki, Junichi; Shimada, Nobuyoshi; Takahashi, Katsutoshi; Takita, Tomohisa; Takeuchi, Tomio; Hoshino, Hiroo
CS Sch. Med., Gunma Univ., Maebashi, 371, Japan
SO Antimicrobial Agents and Chemotherapy (1989), 33(5), 773-5
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English
CC 1-5 (Pharmacology)
GI



I

AB Oxetanocin A (I) is a novel nucleoside contg. a 4-membered sugar, oxetanosyl-N-glycoside, and adenine. The effects of oxetanocin and related compds. on the infectivity of human immunodeficiency virus (**HIV**) were examd. They inhibited **HIV** infectivity in vitro. Allopurinol and mycophenolic acid produced additive anti-**HIV** effects when added with these compds.
ST oxetanocin analog human immunodeficiency virus
IT Virus, animal
(human immunodeficiency 1, inhibition of, by oxetanocin analogs, allopurinol and mycophenolic acid enhancement of)
IT 315-30-0 **24280-93-1**, Mycophenolic acid
RL: BIOL (Biological study)
(human immunodeficiency virus inhibition by oxetanocin analogs enhancement by)
IT 103913-16-2 113269-44-6 113269-45-7 113269-46-8 113296-23-4
RL: BIOL (Biological study)
(human immunodeficiency virus inhibition by, allopurinol and mycophenolic acid enhancement of)

=>

AN 1989:449969 CAPLUS
DN 111:49969
TI Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compounds
AU Seki, Junichi; Shimada, Nobuyoshi; Takahashi, Katsutoshi; Takita, Tomohisa; Takeuchi, Tomio; Hoshino, Hiroo
CS Sch. Med., Gunma Univ., Maebashi, 371, Japan
SO Antimicrobial Agents and Chemotherapy (1989), 33(5), 773-5
CODEN: AMACCQ; ISSN: 0066-4804
DT Journal
LA English
CC 1-5 (Pharmacology)
GI



I

AB Oxetanocin A (I) is a novel nucleoside contg. a 4-membered sugar, oxetanosyl-N-glycoside, and adenine. The effects of oxetanocin and related compds. on the infectivity of human immunodeficiency virus (**HIV**) were examd. They inhibited **HIV** infectivity in vitro. Allopurinol and mycophenolic acid produced additive anti-**HIV** effects when added with these compds.
ST oxetanocin analog human immunodeficiency virus
IT Virus, animal
(human immunodeficiency 1, inhibition of, by oxetanocin analogs, allopurinol and mycophenolic acid enhancement of)
IT 315-30-0 **24280-93-1**, Mycophenolic acid
RL: BIOL (Biological study)
(human immunodeficiency virus inhibition by oxetanocin analogs enhancement by)
IT 103913-16-2 113269-44-6 113269-45-7 113269-46-8 113296-23-4
RL: BIOL (Biological study)
(human immunodeficiency virus inhibition by, allopurinol and mycophenolic acid enhancement of)

=>

AN 1991:400257 CAPLUS
DN 115:257
TI Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside
AU Balzarini, Jan; Naesens, Lieve; Robins, Morris J.; De Clercq, Erik
CS Rega Inst. Med. Res., Cathol. Univ. Leuven, Louvain, B-3000, Belg.
SO Journal of Acquired Immune Deficiency Syndromes (1990), 3(12), 1140-7
CODEN: JAISET; ISSN: 0894-9255
DT Journal
LA English
CC 1-5 (Pharmacology)
AB The nucleoside analogs, 2',3'-dideoxyinosine (DDI) and 2',3'-dideoxy-2,6-diaminopurine riboside (ddDAPR) are potent and selective inhibitors of human immunodeficiency virus (**HIV**) replication in MT-4 cells. They are also inhibitory to the transformation of C3H/3T3 cells by Moloney murine sarcoma virus (MSV). In vivo, they are only marginally effective in delaying MSV-induced tumor formation, and mortality assocd. therewith in newborn NMRI mice. When combined with ribavirin, DDI and ddDAPR become much more effective in inhibiting MSV and **HIV** replication in vitro and MSV-induced tumor formation in vivo. These observations point to the potential role of ribavirin in the treatment of **retrovirus** infections, particularly in potentiating the anti-**HIV** activity of DDI in AIDS patients.
ST ribavirin deoxynucleoside **retrovirus** inhibition; human immunodeficiency virus inhibition ribavirin deoxynucleoside; **HIV** inhibition ribavirin deoxynucleoside
IT Virucides and Virustats
(dideoxynucleoside-ribavirin combinations as, against **retrovirus**, in human and lab. animal cells)
IT Nucleosides, biological studies
RL: BIOL (Biological study)
(dideoxy, **retrovirus** inhibition by ribavirin and, in human and lab. animal cells)
IT Virus, animal
(human immunodeficiency 1, inhibition of, by dideoxynucleoside-ribavirin combinations, in human cells)
IT Virus, animal
(retro-, inhibition of, by dideoxynucleoside-ribavirin combinations, in human and lab. animal cells)
IT **36791-04-5**, Ribavirin
RL: BIOL (Biological study)
(**retrovirus** inhibition by dideoxynucleosides and, in human and lab. animal cells)
IT 69655-05-6, 2',3'-Dideoxyinosine 107550-73-2
RL: BIOL (Biological study)
(**retrovirus** inhibition by ribavirin and, in human and lab. animal cells)

=>

AN 1991:400257 CAPLUS
DN 115:257
TI Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside
AU Balzarini, Jan; Naesens, Lieve; Robins, Morris J.; De Clercq, Erik
CS Rega Inst. Med. Res., Cathol. Univ. Leuven, Louvain, B-3000, Belg.
SO Journal of Acquired Immune Deficiency Syndromes (1990), 3(12), 1140-7
CODEN: JAISET; ISSN: 0894-9255
DT Journal
LA English
CC 1-5 (Pharmacology)
AB The nucleoside analogs, 2',3'-dideoxyinosine (DDI) and 2',3'-dideoxy-2,6-diaminopurine riboside (ddDAPR) are potent and selective inhibitors of human immunodeficiency virus (**HIV**) replication in MT-4 cells. They are also inhibitory to the transformation of C3H/3T3 cells by Moloney murine sarcoma virus (MSV). In vivo, they are only marginally effective in delaying MSV-induced tumor formation, and mortality assocd. therewith in newborn NMRI mice. When combined with ribavirin, DDI and ddDAPR become much more effective in inhibiting MSV and **HIV** replication in vitro and MSV-induced tumor formation in vivo. These observations point to the potential role of ribavirin in the treatment of **retrovirus** infections, particularly in potentiating the anti-**HIV** activity of DDI in AIDS patients.
ST ribavirin deoxynucleoside **retrovirus** inhibition; human immunodeficiency virus inhibition ribavirin deoxynucleoside; **HIV** inhibition ribavirin deoxynucleoside
IT Virucides and Virustats
(dideoxynucleoside-ribavirin combinations as, against **retrovirus**, in human and lab. animal cells)
IT Nucleosides, biological studies
RL: BIOL (Biological study)
(dideoxy, **retrovirus** inhibition by ribavirin and, in human and lab. animal cells)
IT Virus, animal
(human immunodeficiency 1, inhibition of, by dideoxynucleoside-ribavirin combinations, in human cells)
IT Virus, animal
(retro-, inhibition of, by dideoxynucleoside-ribavirin combinations, in human and lab. animal cells)
IT **36791-04-5**, Ribavirin
RL: BIOL (Biological study)
(**retrovirus** inhibition by dideoxynucleosides and, in human and lab. animal cells)
IT 69655-05-6, 2',3'-Dideoxyinosine 107550-73-2
RL: BIOL (Biological study)
(**retrovirus** inhibition by ribavirin and, in human and lab. animal cells)

=>

AN 1991:55350 CAPLUS
DN 114:55350
TI Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase
AU Fernandez-Larsson, Roberto; Patterson, Jean L.
CS Div. Infect. Dis., Child. Hosp., Boston, MA, 02115, USA
SO Molecular Pharmacology (1990), 38(6), 766-70
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English
CC 1-5 (Pharmacology)
AB Ribavirin inhibits the human immunodeficiency virus reverse transcriptase in an in vitro reaction. Ribavirin-5'-diphosphate was close to 40% more inhibitory than ribavirin-5'-triphosphate. Unphosphorylated ribavirin had a reduced, but detectable, effect as an inhibitor, compared with the phosphorylated forms. The compds. seem to have a direct effect on the viral polymerase, and no chain termination was obsd. in the presence of ribavirin-5'-triphosphate. Combination of any of the ribavirin derivs. tested with 3'-azido-3'-deoxythymidine (zidovudine)-5'-triphosphate resulted in an increase of its anti-human immunodeficiency virus reverse transcriptase activity in the in vitro assay.
ST ribavirin **HIV** 1 reverse transcriptase inhibitor
IT Virus, animal
(human immunodeficiency 1, reverse transcriptase of, inhibition by ribavirin and phosphorylated ribavirin and zidovudine)
IT Microbicidal and microbiostatic action
(virucidal, of ribavirin and phosphorylated ribavirin and zidovudine)
IT **36791-04-5**, Ribavirin **63142-70-1**, Ribavirin-5'-diphosphate **63142-71-2**, Ribavirin-5'-triphosphate
RL: BIOL (Biological study)
(**HIV**-1 reverse transcriptase inhibition by)
IT 92586-35-1, Zidovudine-5'-triphosphate
RL: BIOL (Biological study)
(**HIV**-1 reverse transcriptase inhibition by phosphorylated ribavirin and)
IT 9012-90-2, DNA polymerase 9068-38-6, Reverse transcriptase
RL: BIOL (Biological study)
(of **HIV**-1, inhibition by ribavirin and phosphorylated ribavirin and zidovudine)

=>

DN 123:160186
TI Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus
AU Ichimura, Hiroshi; Levy, Jay A.
CS Cancer Res. Inst., Univ. California, San Francisco, CA, 94143, USA
SO Virology (1995), 211(2), 554-60
CODEN: VIRLAX; ISSN: 0042-6822
PB Academic
DT Journal
LA English
CC 1-5 (Pharmacology)
AB Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase, shows strong anti-**HIV** activity in vitro in both human peripheral blood CD4+ lymphocytes and macrophages, as well as established human cell lines. MPA shows its greatest antiviral effects during the early stages of **HIV** infection. By limiting the rate of de novo synthesis of guanosine nucleotides, this drug apparently blocks the activity of reverse transcriptase, which is required for the formation of the **HIV** DNA provirus. MPA provides a novel strategy for inhibiting the replication of **HIV** and should be considered in clin. trials of antiviral therapies.
ST polymerase substrate depletion **HIV** replication; mycophenolic acid **HIV** inhibition reverse transcriptase
IT Blood
Lymphocyte
Macrophage
Virucides and Virustats
(**HIV**-1 reverse transcriptase inhibition and polymerase substrate depletion by mycophenolic acid)
IT Nucleotides, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibition of guanosine nucleotides by mycophenolic acid and anti-**HIV**-1 activity)
IT Virus, animal
(human immunodeficiency 1, **HIV**-1 reverse transcriptase inhibition and polymerase substrate depletion by mycophenolic acid)
IT **24280-93-1**, Mycophenolic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**HIV**-1 reverse transcriptase inhibition and polymerase substrate depletion by mycophenolic acid)
IT 9068-38-6, Reverse transcriptase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**HIV**-1 reverse transcriptase inhibition and polymerase substrate depletion by mycophenolic acid)
IT 118-00-3D, Guanosine, nucleotides
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibition of guanosine nucleotides by mycophenolic acid and anti-**HIV**-1 activity)

=>